Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06808984 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

A Phase 2 study of Alzheimer Disease and Agitation, sponsored by Celgene.

Recruiting
Registry status
Phase 2
Development phase
120
Enrollment target
20
Study locations

NCT06808984 is a Phase 2 study of Alzheimer Disease and Agitation that is actively recruiting participants, run by Celgene. The registered enrollment target is 120 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06808984, a Phase 2 study of Alzheimer Disease and Agitation, is actively recruiting participants, sponsored by Celgene.

RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

Conditions Studied

Alzheimer Disease Agitation

Interventions

  • DRUG Placebo
  • DRUG BMS-986368

Study Locations (20)

California

  • Local Institution - 0017 - Anaheim
  • Inland Psychiatric Medical Group, Inc - Chino
  • Kaizen Brain Center - La Jolla
  • University of California San Diego - La Jolla - La Jolla
  • Shreenath Clinical Service - Lakewood - Lakewood
  • Accellacare - Sherman Oaks - Sherman Oaks
  • Next Level Clinical Trials - West Covina
  • Alliance Clinical -West Hills - West Hills

Florida

  • Arrow Clinical Trials - Daytona Beach
  • ClinCloud - Maitland
  • Local Institution - 0007 - Maitland
  • Local Institution - 0022 - Miami
  • Ocean Blue Medical Research Center - Miami
  • Local Institution - 0001 - Tampa

Alabama

  • Local Institution - 0046 - Homewood
  • University of Alabama - Huntsville Regional Medical Campus - Huntsville

Arizona

  • NoesisPharma - Phoenix
  • Local Institution - 0040 - Scottsdale

Colorado

  • Local Institution - 0066 - Aurora

District of Columbia

  • Local Institution - 0053 - Washington D.C.

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-06-09
Est. Completion 2028-01-07
Phase Phase 2

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06808984

The ClinicalTrials.gov registry entry for NCT06808984 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06808984 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT06808984 about?

NCT06808984 is a clinical study titled "Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease". This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

What is the current status of trial NCT06808984?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-06-09. Estimated completion is 2028-01-07.

What conditions does trial NCT06808984 study?

This clinical trial studies the following conditions: Alzheimer Disease, Agitation.

What interventions are being tested in trial NCT06808984?

The interventions under investigation include: Placebo (DRUG), BMS-986368 (DRUG).

Who is sponsoring clinical trial NCT06808984?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06808984 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Agitation

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.